Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Bladder Cancer

  Free Subscription


Articles published in Anticancer Res

Retrieve available abstracts of 53 articles:
HTML format
Text format



Single Articles


    June 2018
  1. MOURMOURAS N, Philippou A, Christopoulos P, Kostoglou K, et al
    Differential Expression of IGF-I Transcripts in Bladder Cancer.
    Anticancer Res. 2018;38:3453-3459.
    PubMed     Text format     Abstract available


  2. POSFAI B, Kuthi L, Varga L, Laczo I, et al
    The Colorful Palette of Neuroendocrine Neoplasms in the Genitourinary Tract.
    Anticancer Res. 2018;38:3243-3254.
    PubMed     Text format     Abstract available


    May 2018
  3. REXIN P, Tauchert A, Hanze J, Heers H, et al
    The Immune Checkpoint Molecule CD200 Is Associated with Tumor Grading and Metastasis in Bladder Cancer.
    Anticancer Res. 2018;38:2749-2754.
    PubMed     Text format     Abstract available


  4. OWARI T, Miyake M, Nakai Y, Morizawa Y, et al
    A Genitourinary Cancer-specific Scoring System for the Prediction of Survival in Patients with Bone Metastasis: A Retrospective Analysis of Prostate Cancer, Renal Cell Carcinoma, and Urothelial Carcinoma.
    Anticancer Res. 2018;38:3097-3103.
    PubMed     Text format     Abstract available


    April 2018
  5. KIM S, Lee AJ, Yeo MK, Na YG, et al
    Clinicopathological Profiling of LC3B, an Autophagy Marker, and ESRRA (Estrogen-related Receptor-alpha) in Muscle-invasive Bladder Cancer.
    Anticancer Res. 2018;38:2429-2437.
    PubMed     Text format     Abstract available


  6. MATSUNAGA W, Ichikawa M, Nakamura A, Ishikawa T, et al
    Lentiviral Vector-mediated Gene Transfer in Human Bladder Cancer Cell Lines.
    Anticancer Res. 2018;38:2015-2020.
    PubMed     Text format     Abstract available


  7. MAKINO T, Izumi K, Natsagdorj A, Iwamoto H, et al
    Significance of Perioperative Chemotherapy in Squamous Cell Carcinoma of the Upper and Lower Urinary Tract.
    Anticancer Res. 2018;38:2241-2245.
    PubMed     Text format     Abstract available


    March 2018
  8. MIYATA Y, Matsuo T, Nakamura Y, Yasuda T, et al
    Expression of Class III Beta-tubulin Predicts Prognosis in Patients with Cisplatin-resistant Bladder Cancer Receiving Paclitaxel-based Second-line Chemotherapy.
    Anticancer Res. 2018;38:1629-1635.
    PubMed     Text format     Abstract available


  9. MICHALSKA M, Schultze-Seemann S, Kuckuck I, Katzenwadel A, et al
    Impact of Methadone on Cisplatin Treatment of Bladder Cancer Cells.
    Anticancer Res. 2018;38:1369-1375.
    PubMed     Text format     Abstract available


    February 2018
  10. HEERS H, Gut JM, Hegele A, Hofmann R, et al
    Non-invasive Detection of Bladder Tumors Through Volatile Organic Compounds: A Pilot Study with an Electronic Nose.
    Anticancer Res. 2018;38:833-837.
    PubMed     Text format     Abstract available


    January 2018
  11. SOUKUP V, Capoun O, Pesl M, Sobotka R, et al
    Placental Growth Factor in Bladder Cancer Compared to the Diagnostic Accuracy and Prognostic Performance of Vascular Endothelial Growth Factor A.
    Anticancer Res. 2018;38:239-246.
    PubMed     Text format     Abstract available


    December 2017
  12. CHEN CC, Huang CP, Tsai YT, Hseih TF, et al
    The Genomic Alterations of 5alpha-Reductases and Their Inhibitor Finasteride's Effect in Bladder Cancer.
    Anticancer Res. 2017;37:6893-6898.
    PubMed     Text format     Abstract available


  13. MINAMI S, Matsumoto K, Nagashio R, Hagiuda D, et al
    Analysis of Autoantibodies Related to Tumor Progression in Sera from Patients with High-grade Non-muscle-invasive Bladder Cancer.
    Anticancer Res. 2017;37:6705-6714.
    PubMed     Text format     Abstract available


  14. SYRING I, Weiten R, Muller T, Schmidt D, et al
    The Contrasting Role of the Mediator Subunit MED30 in the Progression of Bladder Cancer.
    Anticancer Res. 2017;37:6685-6695.
    PubMed     Text format     Abstract available


    November 2017
  15. SCHINZARI G, Monterisi S, Pierconti F, Nazzicone G, et al
    Neoadjuvant Chemotherapy for Patients with Muscle-invasive Urothelial Bladder Cancer Candidates for Curative Surgery: A Prospective Clinical Trial Based on Cisplatin Feasibility.
    Anticancer Res. 2017;37:6453-6458.
    PubMed     Text format     Abstract available


  16. LIAW CC, Chuang CK, Chang YH, Liao TY, et al
    Bladder Urothelial Carcinoma with Peritoneal Involvement: Benefit of Continuous Maintenance Chemotherapy.
    Anticancer Res. 2017;37:6443-6451.
    PubMed     Text format     Abstract available


    October 2017
  17. AIZAWA R, Sakamoto M, Orito N, Kono M, et al
    The Use of External-beam Radiotherapy for Muscle-invasive Bladder Cancer in Elderly or Medically-fragile Patients.
    Anticancer Res. 2017;37:5761-5766.
    PubMed     Text format     Abstract available


  18. HAQUE W, Verma V, Butler EB, Teh BS, et al
    Radical Cystectomy Versus Chemoradiation for Muscle-invasive Bladder Cancer: Impact of Treatment Facility and Sociodemographics.
    Anticancer Res. 2017;37:5603-5608.
    PubMed     Text format     Abstract available


  19. D'ANDREA D, Moschini M, Soria F, Gust KM, et al
    ABO Blood Group and Rhesus Factor Are Not Associated with Outcomes After Radical Cystectomy for Non-metastatic Urothelial Carcinoma of the Bladder.
    Anticancer Res. 2017;37:5747-5753.
    PubMed     Text format     Abstract available


    September 2017
  20. CIMPEAN AM, Tarlui V, Cumpanas AA, Bolintineanu S, et al
    Critical Overview of HER2 Assessement in Bladder Cancer: What Is Missing for a Better Therapeutic Approach?
    Anticancer Res. 2017;37:4935-4942.
    PubMed     Text format     Abstract available


  21. HSU FT, Sun CC, Wu CH, Lee YJ, et al
    Regorafenib Induces Apoptosis and Inhibits Metastatic Potential of Human Bladder Carcinoma Cells.
    Anticancer Res. 2017;37:4919-4926.
    PubMed     Text format     Abstract available


    August 2017
  22. TANG X, Wang S, An C, DU P, et al
    Preoperative High Neutrophil-to-Lymphocyte Ratio Is Associated with High-grade Bladder Cancer.
    Anticancer Res. 2017;37:4659-4663.
    PubMed     Text format     Abstract available


  23. ZHOU HH, Liu LY, Yu GH, Qu GM, et al
    Analysis of Clinicopathological Features and Prognostic Factors in 39 Cases of Bladder Neuroendocrine Carcinoma.
    Anticancer Res. 2017;37:4529-4537.
    PubMed     Text format     Abstract available


  24. DU P, Wang S, Tang X, An C, et al
    Reduced Expression of Metastasis Suppressor-1 (MTSS1) Accelerates Progression of Human Bladder Uroepithelium Cell Carcinoma.
    Anticancer Res. 2017;37:4499-4505.
    PubMed     Text format     Abstract available


    July 2017
  25. ORYWAL K, Jelski W, Werel T, Szmitkowski M, et al
    The Diagnostic Significance of Serum Alcohol Dehydrogenase Isoenzymes and Aldehyde Dehydrogenase Activity in Urinary Bladder Cancer Patients.
    Anticancer Res. 2017;37:3537-3541.
    PubMed     Text format     Abstract available


    June 2017
  26. JANSSEN S, Manig L, Schild SE, Rades D, et al
    Radiotherapy of Primary or Recurrent Bladder Cancer in the Very Elderly.
    Anticancer Res. 2017;37:3287-3290.
    PubMed     Text format     Abstract available


    May 2017
  27. MANIG L, Kasmann L, Janssen S, Schild SE, et al
    Simplified Comorbidity Score and Eastern Cooperative Oncology Group Performance Score Predicts Survival in Patients Receiving Organ-preserving Treatment for Bladder Cancer.
    Anticancer Res. 2017;37:2693-2696.
    PubMed     Text format     Abstract available


    April 2017
  28. SILVA J, Arantes-Rodrigues R, Pinto-Leite R, Faustino-Rocha AI, et al
    Synergistic Effect of Carboplatin and Piroxicam on Two Bladder Cancer Cell Lines.
    Anticancer Res. 2017;37:1737-1745.
    PubMed     Text format     Abstract available


  29. KHANAL A, Budhathoki N, Singh VP, Shah BK, et al
    Second Primary Malignancy in Bladder Carcinoma - A Population-based Study.
    Anticancer Res. 2017;37:2033-2036.
    PubMed     Text format     Abstract available


    March 2017
  30. RADES D, Manig L, Janssen S, Schild SE, et al
    Concurrent Chemotherapy Improves the Overall Survival of Patients Irradiated for Locally Recurrent Bladder Cancer.
    Anticancer Res. 2017;37:1485-1488.
    PubMed     Text format     Abstract available


  31. RADES D, Manig L, Janssen S, Schild SE, et al
    A Survival Score for Patients Assigned to Palliative Radiotherapy for Metastatic Bladder Cancer.
    Anticancer Res. 2017;37:1481-1484.
    PubMed     Text format     Abstract available


  32. HUDOLIN T, Mengus C, Coulot J, Kastelan Z, et al
    Expression of Indoleamine 2,3-Dioxygenase Gene Is a Feature of Poorly Differentiated Non-muscle-invasive Urothelial Cell Bladder Carcinomas.
    Anticancer Res. 2017;37:1375-1380.
    PubMed     Text format     Abstract available


  33. SHI CS, Li JM, Chin CC, Kuo YH, et al
    Evodiamine Induces Cell Growth Arrest, Apoptosis and Suppresses Tumorigenesis in Human Urothelial Cell Carcinoma Cells.
    Anticancer Res. 2017;37:1149-1159.
    PubMed     Text format     Abstract available


    February 2017
  34. WIECZOREK E, Jablonowski Z, Tomasik B, Gromadzinska J, et al
    Different Gene Expression and Activity Pattern of Antioxidant Enzymes in Bladder Cancer.
    Anticancer Res. 2017;37:841-848.
    PubMed     Text format     Abstract available


  35. FRIEDMAN P, Lai JP
    Liver Metastasis of Urothelial Carcinoma with Hepatoid Features: An Unusual Morphological Finding.
    Anticancer Res. 2017;37:801-804.
    PubMed     Text format     Abstract available


    December 2016
  36. MANIG L, Kasmann L, Janssen S, Rades D, et al
    Predicting Survival After Irradiation of Metastases from Transitional Carcinoma of the Bladder.
    Anticancer Res. 2016;36:6663-6665.
    PubMed     Text format     Abstract available


  37. HANCOCK BM, McGuire KL, Tsuji S, Reil K, et al
    A Single Intravesical Instillation of VAX014 Inhibits Orthotopic Superficial Bladder Tumor Implantation to Increase Survival.
    Anticancer Res. 2016;36:6243-6248.
    PubMed     Text format     Abstract available


    October 2016
  38. SAKAGUCHI M, Maebayashi T, Aizawa T, Ishibashi N, et al
    Clinical Results for Bladder Cancer Treated by Radiotherapy Without Concurrent Standard Chemotherapy.
    Anticancer Res. 2016;36:5519-5525.
    PubMed     Text format     Abstract available


  39. KRIEGMAIR MC, Balk M, Wirtz R, Steidler A, et al
    Expression of the p53 Inhibitors MDM2 and MDM4 as Outcome Predictor in Muscle-invasive Bladder Cancer.
    Anticancer Res. 2016;36:5205-5213.
    PubMed     Text format     Abstract available


  40. IWAMOTO H, Izumi K, Shimura Y, Natsagdorj A, et al
    Metastasectomy Improves Survival in Patients with Metastatic Urothelial Carcinoma.
    Anticancer Res. 2016;36:5557-5561.
    PubMed     Text format     Abstract available


    September 2016
  41. MAEBAYASHI T, Ishibashi N, Aizawa T, Sakaguchi M, et al
    Radiotherapy for Muscle-invasive Bladder Cancer in Very Elderly Patients.
    Anticancer Res. 2016;36:4763-9.
    PubMed     Text format     Abstract available


  42. CHANG WS, Liao CH, Tsai CW, Hu PS, et al
    Association of Enhancer of Zeste 2 (EZH2) Genotypes with Bladder Cancer Risk in Taiwan.
    Anticancer Res. 2016;36:4509-14.
    PubMed     Text format     Abstract available


    August 2016
  43. ELLINGER J, Schneider AC, Bachmann A, Kristiansen G, et al
    Evaluation of Global Histone Acetylation Levels in Bladder Cancer Patients.
    Anticancer Res. 2016;36:3961-4.
    PubMed     Text format     Abstract available


  44. HAHN AW, Giri S, Pathak R, Bhatt VR, et al
    Effect of Adjuvant Radiotherapy on Survival in Patients with Locoregional Urothelial Malignancies of the Upper Urinary Tract.
    Anticancer Res. 2016;36:4051-5.
    PubMed     Text format     Abstract available


    April 2016
  45. LENORMAND C, Couteau J, Nouhaud FX, Maillet G, et al
    Predictive Value of NRAMP1 and HGPX1 Gene Polymorphism for Maintenance BCG Response in Non-muscle-invasive Bladder Cancer.
    Anticancer Res. 2016;36:1737-43.
    PubMed     Text format     Abstract available


  46. NAKAGAWA YU, Nagaya H, Miyata T, Wada Y, et al
    Piperazine-based Alpha-1 AR Blocker, Naftopidil, Selectively Suppresses Malignant Human Bladder Cells via Induction of Apoptosis.
    Anticancer Res. 2016;36:1563-70.
    PubMed     Text format     Abstract available


    February 2016
  47. KIYOSHIMA K, Akitake M, Shiota M, Takeuchi A, et al
    Prognostic Significance of Preoperative Urine Cytology in Low-grade Non-muscle-invasive Bladder Cancer.
    Anticancer Res. 2016;36:799-802.
    PubMed     Text format     Abstract available


  48. YOSHIOKA H, Shimbo T, Yoshida K, Yoshikawa N, et al
    Treatment Results of Radiotherapy Combined with Balloon-occluded Arterial Infusion Chemotherapy for Invasive Bladder Cancer.
    Anticancer Res. 2016;36:731-6.
    PubMed     Text format     Abstract available


  49. KILARI D, Iczkowski KA, Pandya C, Robin AJ, et al
    Copper Transporter-CTR1 Expression and Pathological Outcomes in Platinum-treated Muscle-invasive Bladder Cancer Patients.
    Anticancer Res. 2016;36:495-501.
    PubMed     Text format     Abstract available


    November 2015
  50. LEA MA, Altayyar M, desBORDES C
    Inhibition of Growth of Bladder Cancer Cells by 3-(3-Pyridinyl)-1-(4-pyridinyl)-2-propen-1-one in Combination with Other Compounds Affecting Glucose Metabolism.
    Anticancer Res. 2015;35:5889-99.
    PubMed     Text format     Abstract available


    September 2015
  51. NOEL N, Couteau J, Maillet G, Gobet F, et al
    TP53 and FGFR3 Gene Mutation Assessment in Urine: Pilot Study for Bladder Cancer Diagnosis.
    Anticancer Res. 2015;35:4915-21.
    PubMed     Text format     Abstract available


    May 2015
  52. ECKE TH, Arndt C, Stephan C, Hallmann S, et al
    Preliminary Results of a Multicentre Study of the UBC Rapid Test for Detection of Urinary Bladder Cancer.
    Anticancer Res. 2015;35:2651-5.
    PubMed     Text format     Abstract available


  53. SULE N, Xu BO, El Zein D, Szigeti K, et al
    Radiation-induced Chondrosarcoma of the Bladder. Case Report and Review of Literature.
    Anticancer Res. 2015;35:2857-60.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: